Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells

Bibliographic Details
Main Author: Zhang,Lei
Publication Date: 2017
Other Authors: Zhou,Xian-Jin, Zhan,Li-Ying, Wu,Xiao-Jing, Li,Wen-Lan, Zhao,Bo, Meng,Qing-Tao, Xia,Zhong-Yuan
Format: Article
Language: eng
Source: Revista Brasileira de Anestesiologia (Online)
Download full: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942017000600600
Summary: Abstract Background and objectives Dexmedetomidine (DEX) has demonstrated the preconditioning effect and shown protective effects against organize injury. In this study, using A549 (human alveolar epithelial cell) cell lines, we investigated whether DEX preconditioning protected against acute lung injury (ALI) in vitro. Methods A549 were randomly divided into four groups (n = 5): control group, DEX group, lipopolysaccharides (LPS) group, and D-LPS (DEX + LPS) group. Phosphate buffer saline (PBS) or DEX were administered. After 2 h preconditioning, the medium was refreshed and the cells were challenged with LPS for 24 h on the LPS and D-LPS group. Then the malondialdehyde (MDA), superoxide dismutase (SOD), Bcl-2, Bax, caspase-3 and the cytochrome c in the A549 were tested. The apoptosis was also evaluated in the cells. Results Compare with LPS group, DEX preconditioning reduced the apoptosis (26.43% ± 1.05% vs. 33.58% ± 1.16%, p < 0.05) in the A549, which is correlated with decreased MDA (12.84 ± 1.05 vs. 19.16 ± 1.89 nmoL.mg-1 protein, p < 0.05) and increased SOD activity (30.28 ± 2.38 vs. 20.86 ± 2.19 U.mg-1 protein, p < 0.05). DEX preconditioning also increased the Bcl-2 level (0.53 ± 0.03 vs. 0.32 ± 0.04, p < 0.05) and decreased the level of Bax (0.49 ± 0.04 vs. 0.65 ± 0.04, p < 0.05), caspase-3 (0.54 ± 0.04 vs. 0.76 ± 0.04, p < 0.05) and cytochrome c. Conclusion DEX preconditioning has a protective effect against ALI in vitro. The potential mechanisms involved are the inhibition of cell death and improvement of antioxidation.
id SBA-1_2d9f7957b5ae94a777b529dbc00a9c92
oai_identifier_str oai:scielo:S0034-70942017000600600
network_acronym_str SBA-1
network_name_str Revista Brasileira de Anestesiologia (Online)
repository_id_str
spelling Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cellsDexmedetomidineLipopolysaccharidesPreconditioningAcute lung injuryAlveolar epithelial cellAbstract Background and objectives Dexmedetomidine (DEX) has demonstrated the preconditioning effect and shown protective effects against organize injury. In this study, using A549 (human alveolar epithelial cell) cell lines, we investigated whether DEX preconditioning protected against acute lung injury (ALI) in vitro. Methods A549 were randomly divided into four groups (n = 5): control group, DEX group, lipopolysaccharides (LPS) group, and D-LPS (DEX + LPS) group. Phosphate buffer saline (PBS) or DEX were administered. After 2 h preconditioning, the medium was refreshed and the cells were challenged with LPS for 24 h on the LPS and D-LPS group. Then the malondialdehyde (MDA), superoxide dismutase (SOD), Bcl-2, Bax, caspase-3 and the cytochrome c in the A549 were tested. The apoptosis was also evaluated in the cells. Results Compare with LPS group, DEX preconditioning reduced the apoptosis (26.43% ± 1.05% vs. 33.58% ± 1.16%, p < 0.05) in the A549, which is correlated with decreased MDA (12.84 ± 1.05 vs. 19.16 ± 1.89 nmoL.mg-1 protein, p < 0.05) and increased SOD activity (30.28 ± 2.38 vs. 20.86 ± 2.19 U.mg-1 protein, p < 0.05). DEX preconditioning also increased the Bcl-2 level (0.53 ± 0.03 vs. 0.32 ± 0.04, p < 0.05) and decreased the level of Bax (0.49 ± 0.04 vs. 0.65 ± 0.04, p < 0.05), caspase-3 (0.54 ± 0.04 vs. 0.76 ± 0.04, p < 0.05) and cytochrome c. Conclusion DEX preconditioning has a protective effect against ALI in vitro. The potential mechanisms involved are the inhibition of cell death and improvement of antioxidation.Sociedade Brasileira de Anestesiologia2017-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942017000600600Revista Brasileira de Anestesiologia v.67 n.6 2017reponame:Revista Brasileira de Anestesiologia (Online)instname:Sociedade Brasileira de Anestesiologia (SBA)instacron:SBA10.1016/j.bjane.2017.02.002info:eu-repo/semantics/openAccessZhang,LeiZhou,Xian-JinZhan,Li-YingWu,Xiao-JingLi,Wen-LanZhao,BoMeng,Qing-TaoXia,Zhong-Yuaneng2017-11-29T00:00:00Zoai:scielo:S0034-70942017000600600Revistahttps://www.sbahq.org/revista/https://old.scielo.br/oai/scielo-oai.php||sba2000@openlink.com.br1806-907X0034-7094opendoar:2017-11-29T00:00Revista Brasileira de Anestesiologia (Online) - Sociedade Brasileira de Anestesiologia (SBA)false
dc.title.none.fl_str_mv Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
title Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
spellingShingle Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
Zhang,Lei
Dexmedetomidine
Lipopolysaccharides
Preconditioning
Acute lung injury
Alveolar epithelial cell
title_short Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
title_full Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
title_fullStr Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
title_full_unstemmed Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
title_sort Dexmedetomidine preconditioning protects against lipopolysaccharides-induced injury in the human alveolar epithelial cells
author Zhang,Lei
author_facet Zhang,Lei
Zhou,Xian-Jin
Zhan,Li-Ying
Wu,Xiao-Jing
Li,Wen-Lan
Zhao,Bo
Meng,Qing-Tao
Xia,Zhong-Yuan
author_role author
author2 Zhou,Xian-Jin
Zhan,Li-Ying
Wu,Xiao-Jing
Li,Wen-Lan
Zhao,Bo
Meng,Qing-Tao
Xia,Zhong-Yuan
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Zhang,Lei
Zhou,Xian-Jin
Zhan,Li-Ying
Wu,Xiao-Jing
Li,Wen-Lan
Zhao,Bo
Meng,Qing-Tao
Xia,Zhong-Yuan
dc.subject.por.fl_str_mv Dexmedetomidine
Lipopolysaccharides
Preconditioning
Acute lung injury
Alveolar epithelial cell
topic Dexmedetomidine
Lipopolysaccharides
Preconditioning
Acute lung injury
Alveolar epithelial cell
description Abstract Background and objectives Dexmedetomidine (DEX) has demonstrated the preconditioning effect and shown protective effects against organize injury. In this study, using A549 (human alveolar epithelial cell) cell lines, we investigated whether DEX preconditioning protected against acute lung injury (ALI) in vitro. Methods A549 were randomly divided into four groups (n = 5): control group, DEX group, lipopolysaccharides (LPS) group, and D-LPS (DEX + LPS) group. Phosphate buffer saline (PBS) or DEX were administered. After 2 h preconditioning, the medium was refreshed and the cells were challenged with LPS for 24 h on the LPS and D-LPS group. Then the malondialdehyde (MDA), superoxide dismutase (SOD), Bcl-2, Bax, caspase-3 and the cytochrome c in the A549 were tested. The apoptosis was also evaluated in the cells. Results Compare with LPS group, DEX preconditioning reduced the apoptosis (26.43% ± 1.05% vs. 33.58% ± 1.16%, p < 0.05) in the A549, which is correlated with decreased MDA (12.84 ± 1.05 vs. 19.16 ± 1.89 nmoL.mg-1 protein, p < 0.05) and increased SOD activity (30.28 ± 2.38 vs. 20.86 ± 2.19 U.mg-1 protein, p < 0.05). DEX preconditioning also increased the Bcl-2 level (0.53 ± 0.03 vs. 0.32 ± 0.04, p < 0.05) and decreased the level of Bax (0.49 ± 0.04 vs. 0.65 ± 0.04, p < 0.05), caspase-3 (0.54 ± 0.04 vs. 0.76 ± 0.04, p < 0.05) and cytochrome c. Conclusion DEX preconditioning has a protective effect against ALI in vitro. The potential mechanisms involved are the inhibition of cell death and improvement of antioxidation.
publishDate 2017
dc.date.none.fl_str_mv 2017-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942017000600600
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942017000600600
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjane.2017.02.002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Anestesiologia
publisher.none.fl_str_mv Sociedade Brasileira de Anestesiologia
dc.source.none.fl_str_mv Revista Brasileira de Anestesiologia v.67 n.6 2017
reponame:Revista Brasileira de Anestesiologia (Online)
instname:Sociedade Brasileira de Anestesiologia (SBA)
instacron:SBA
instname_str Sociedade Brasileira de Anestesiologia (SBA)
instacron_str SBA
institution SBA
reponame_str Revista Brasileira de Anestesiologia (Online)
collection Revista Brasileira de Anestesiologia (Online)
repository.name.fl_str_mv Revista Brasileira de Anestesiologia (Online) - Sociedade Brasileira de Anestesiologia (SBA)
repository.mail.fl_str_mv ||sba2000@openlink.com.br
_version_ 1752126629536071680